S Gail Eckhardt Selected Research

RX-5902

11/2020	RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
11/2019	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S Gail Eckhardt Research Topics

Disease

121	Neoplasms (Cancer) 01/2022 - 01/2002
29	Colorectal Neoplasms (Colorectal Cancer) 10/2019 - 07/2006
11	Melanoma (Melanoma, Malignant) 01/2021 - 07/2002
9	Triple Negative Breast Neoplasms 11/2020 - 01/2013
6	Neutropenia 04/2016 - 11/2004
6	Nausea 08/2013 - 07/2002
6	Colonic Neoplasms (Colon Cancer) 01/2013 - 07/2006
5	Fatigue 01/2022 - 07/2002
5	Pancreatic Neoplasms (Pancreatic Cancer) 04/2016 - 09/2006
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 11/2004
5	Breast Neoplasms (Breast Cancer) 05/2014 - 05/2006
5	Thrombocytopenia (Thrombopenia) 09/2009 - 09/2006
4	Adenocarcinoma 01/2021 - 09/2006
4	Diarrhea 08/2013 - 07/2002
4	Vomiting 04/2011 - 07/2002
4	Lung Neoplasms (Lung Cancer) 10/2010 - 02/2002
3	Ovarian Neoplasms (Ovarian Cancer) 11/2020 - 02/2011
3	Adenocarcinoma of Lung 01/2019 - 08/2006
3	Exanthema (Rash) 01/2018 - 11/2007
3	Disease Progression 05/2013 - 10/2004
3	Fever (Fevers) 09/2009 - 07/2002
3	Carcinoma (Carcinomatosis) 09/2009 - 08/2005
2	Pain (Aches) 01/2022 - 02/2009
2	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 05/2012
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2021 - 08/2005
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 02/2020 - 09/2009
2	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2016
2	Hypertension (High Blood Pressure) 01/2018 - 02/2011
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 03/2007

Drug/Important Bio-Agent (IBA)

18	Pharmaceutical PreparationsIBA 11/2021 - 07/2002
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2006
15	Phosphotransferases (Kinase)IBA 12/2018 - 07/2006
11	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 11/2006
9	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 08/2007
8	Proteins (Proteins, Gene)FDA Link 11/2021 - 09/2008
7	Biological ProductsIBA 02/2020 - 10/2003
7	AZD 6244IBA 01/2018 - 05/2008
7	Monoclonal AntibodiesIBA 01/2018 - 08/2006
7	ErbB Receptors (EGF Receptor)IBA 10/2010 - 08/2006
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020 - 08/2006
6	Tyrosine Kinase InhibitorsIBA 04/2016 - 11/2007
6	LigandsIBA 03/2015 - 07/2008
6	Docetaxel (Taxotere)FDA Link 03/2010 - 08/2003
5	Capecitabine (Xeloda)FDA Link 01/2021 - 08/2007
5	Gemcitabine FDA Link 04/2016 - 10/2003
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 10/2005
4	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 10/2005
4	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2020
4	PlatinumIBA 11/2020 - 02/2002
4	Aurora Kinase AIBA 01/2020 - 06/2010
4	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 12/2018 - 11/2010
4	EnzymesIBA 01/2018 - 07/2002
4	ENMD 2076IBA 01/2017 - 06/2010
4	vandetanib (ZD6474)IBA 04/2016 - 07/2006
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 04/2016 - 11/2007
4	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 10/2004
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2016 - 09/2008
4	Imatinib Mesylate (Gleevec)FDA Link 02/2013 - 10/2004
4	Cetuximab (Erbitux)FDA Link 10/2010 - 08/2006
4	Tyrosine (L-Tyrosine)FDA Link 06/2010 - 07/2006
3	Histone Deacetylase InhibitorsIBA 01/2022 - 07/2008
3	CateninsIBA 11/2020 - 03/2014
3	AntigensIBA 10/2020 - 01/2017
3	MLN 8237IBA 01/2020 - 05/2015
3	CreatinineIBA 01/2018 - 08/2002
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2018 - 07/2006
3	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2017 - 12/2008
3	IGF Type 1 Receptor (IGF 1 Receptor)IBA 11/2010 - 04/2010
3	Bortezomib (Velcade)FDA Link 10/2010 - 02/2009
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 06/2010 - 08/2006
3	phosphomannopentaose sulfateIBA 03/2010 - 09/2006
3	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 02/2010 - 10/2005
3	Gefitinib (Iressa)FDA Link 04/2009 - 11/2007
2	adavosertibIBA 01/2021 - 03/2020
2	RX-5902IBA 11/2020 - 11/2019
2	Bevacizumab (Avastin)FDA Link 11/2020 - 05/2006
2	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 05/2006
2	c-Mer Tyrosine KinaseIBA 01/2019 - 05/2013
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019 - 05/2013
2	Insulin ReceptorIBA 12/2018 - 11/2013
2	Immunoglobulin G (IgG)IBA 01/2018 - 02/2010
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2018 - 08/2013
2	Protein Kinases (Protein Kinase)IBA 01/2017 - 05/2014
2	Mitogen-Activated Protein KinasesIBA 01/2017 - 10/2010
2	Sorafenib (BAY 43-9006)FDA Link 01/2017 - 10/2010
2	Epidermal Growth Factor (EGF)IBA 04/2016 - 08/2013
2	TAK 733IBA 10/2015 - 02/2015
2	Polo-Like Kinase 1IBA 03/2014 - 04/2012
2	ON 01910IBA 03/2014 - 04/2012
2	Phosphatidylinositols (Phosphatidylinositol)IBA 03/2014 - 05/2012
2	Small Interfering RNA (siRNA)IBA 08/2013 - 05/2013
2	AgarIBA 05/2013 - 10/2010
2	PF 3758309IBA 01/2013 - 01/2013
2	Aurora KinasesIBA 01/2013 - 02/2011

Therapy/Procedure

38	Therapeutics 01/2022 - 02/2002
12	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
7	Immunotherapy 01/2021 - 01/2016
3	Radiotherapy 10/2010 - 10/2008
2	Aftercare (After-Treatment) 01/2017 - 07/2003
2	Drug Tapering 08/2013 - 08/2002